Recently announced by Dendreon Corporation (Nasdaq: DNDN) are data from an exploratory analysis of Phase 3 Studies (D9901 and D9902A) which demonstrated significant correlation between cumulative CD54 upregulation and survival for patients treated with Dendreon's investigational active cellular immunotherapy PROVENGE® (sipuleucel-T) in men with advanced androgen-independent (hormone refractory) prostate cancer.
According to David Urdal, Ph.D., chief scientific officer of Dendreon Corporation:
"CD54 cell count and CD54 upregulation are important biologically-relevant measures used to assess the potency of PROVENGE prior to patient administration.
The demonstration that there is a correlation between cumulative CD54 upregulation and clinical outcome suggests that our potency assay for PROVENGE measures an important and meaningful attribute of this product."
PROVENGE® (sipuleucel-T), an investigational product that may represent the first in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system, is under late-stage clinical development for the treatment of patients with early-stage and advanced prostate cancer.
Find more details of the clinical data from the press release.
Comment Preview